22.03.2012 • NewsGlaxoSmithKline (GSK)GSK

GSK Confirms £500 Million UK Investment Plans

GlaxoSmithKline confirmed plans on Thursday to invest more than 500 million pounds in manufacturing in Britain and said it had selected Ulverston, northern England, as the site for a previously announced biotech plant.

GSK had already said it aimed to ramp up investment and bring more jobs to Britain in response to government plans to reduce the level of corporation tax applied to income from patents - a move known as a patent box.

The confirmation of the investment strategy comes the day after finance minister George Osborne's budget in which he laid out business-friendly tax plans, including reiterating the introduction of the patent box.

Company

GlaxoSmithKline GmbH & Co. KG

Prinzregentenplatz 9
81675 München

Company contact







Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.